InvestorsHub Logo
Followers 78
Posts 10233
Boards Moderated 9
Alias Born 06/06/2017

Re: Viewmont post# 1581

Friday, 02/07/2020 5:05:18 PM

Friday, February 07, 2020 5:05:18 PM

Post# of 1716
This should help move the stock a bit. Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
PR Newswire PR Newswire•February 5, 2020
SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and leukemia, today announced that a poster featuring efficacy data from its Phase 2 study in metastatic castrate-resistant prostate cancer (mCRPC), will be presented on Thursday, February 13th, 2020 at the American Society for Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium in San Francisco.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRDF News